UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

Annals of oncology, 2011-06, Vol.22 (6), p.1413-1419

2011

Volltextzugriff (PDF)

Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization

The Journal of immunology (1950), 1997-03, Vol.158 (5), p.2278-2284

1997

Volltextzugriff (PDF)

Nivolumab (Anti-Programmed Death-1 [PD-1]; BMS-936558) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

Annals of oncology, 2013-03, Vol.24, p.i7-i7

Feltquate, D.M.

2013

Volltextzugriff (PDF)

DNA Immunization for Influenza Virus: Studies Using Hemagglutinin- and Nucleoprotein-Expressing DNAs

The Journal of infectious diseases, 1997-08, Vol.176 (Supplement-1), p.S50-S55

1997

Volltextzugriff (PDF)

Familial hypothyroidism caused by a nonsense mutation in the thyroid-stimulating hormone β-subunit gene

American journal of human genetics, 1990-05, Vol.46 (5), p.988-993

1990

Volltextzugriff (PDF)

DNA vaccines

AIDS research and human retroviruses, 1996-03, Vol.12 (5), p.455-457

1996

Volltextzugriff (PDF)

DNA vaccines: vector design, delivery, and antigen presentation

Journal of cellular biochemistry. Supplement., 1998, Vol.30-31, p.304

Feltquate, D M

1998

Volltextzugriff (PDF)

A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.331-331

2011

Volltextzugriff (PDF)

TaqI and MspI RFLPs are detected by the human 2,3-biphosphoglycerate mutase (BPGM) cDNA

Nucleic acids research, 1990-04, Vol.18 (7), p.1928-1928

1990

Volltextzugriff (PDF)

Effect of CpG methylation on isotype and magnitude of antibody responses to influenza hemagglutinin-expressing plasmid

DNA and cell biology, 1999-09, Vol.18 (9), p.663-670

1999

Volltextzugriff (PDF)

TaqL and MspL RFLPs are detected by the human 2,3-biphosphoglycerate mutase (BPGM) cDNA

Nucleic acids research, 1990-04, Vol.18 (7), p.1928-1928

1990

Volltextzugriff (PDF)

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

British journal of cancer, 2011-06, Vol.105 (1), p.44-52

2011

Volltextzugriff (PDF)

Immune Responses Induced by Gene Gun or Intramuscular Injection of DNA Vaccines That Express Immunogenic Regions of the Serine Repeat Antigen from Plasmodium falciparum

Infection and Immunity, 1999-10, Vol.67 (10), p.5163-5169

1999

Volltextzugriff (PDF)

Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.3007-3007

2008

Volltextzugriff (PDF)

A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4111-4111

2008

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(12)

Publikationsform

Artikel
(15)

Sprache

Englisch
(15)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization

Nivolumab (Anti-Programmed Death-1 [PD-1]; BMS-936558) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

DNA Immunization for Influenza Virus: Studies Using Hemagglutinin- and Nucleoprotein-Expressing DNAs

Familial hypothyroidism caused by a nonsense mutation in the thyroid-stimulating hormone β-subunit gene

DNA vaccines

DNA vaccines: vector design, delivery, and antigen presentation

A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies

TaqI and MspI RFLPs are detected by the human 2,3-biphosphoglycerate mutase (BPGM) cDNA

Effect of CpG methylation on isotype and magnitude of antibody responses to influenza hemagglutinin-expressing plasmid

TaqL and MspL RFLPs are detected by the human 2,3-biphosphoglycerate mutase (BPGM) cDNA

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

Immune Responses Induced by Gene Gun or Intramuscular Injection of DNA Vaccines That Express Immunogenic Regions of the Serine Repeat Antigen from Plasmodium falciparum

Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy

Suchergebnisse filtern